Oncology News | pharmaphorum

News

Mirati challenges Amgen with FDA okay for KRAS drug

Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer.

News

Nordic Nanovector board resigns en masse as merger bid fails

Nordic Nanovector's plan to emerge from its current troubles by merging with APIM Therapeutics has hit an insurmountable hurdle – in the shape of its own shareholders.

News

ASH: J&J makes case for just-filed GPRC5D drug talquetamab

Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new therapeutic approach to multiple myeloma, and told delegates at ASH yesterday why its talquetam

News

ASH: CD20 bispecific antibodies take centre stage in lymphom...

As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with n

News

SABCS: Pharmas show their working in HR+/HER2- breast cancer

The San Antonio Breast Cancer Symposium (SABCS) has highlighted some of the most promising clinical research being undertaken by drugmakers in the category, with AstraZeneca leading the cha

News

SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for cla...

The results of the SERENA-2 trial of AstraZeneca’s oral selective estrogen receptor degrader (SERD) camizestrant, reported at the SABCS congress this week, could restore confidence in the m

Mirati challenges Amgen with FDA okay for KRAS drug

Nordic Nanovector board resigns en masse as merger bid fails

ASH: J&J makes case for just-filed GPRC5D drug talquetamab

ASH: CD20 bispecific antibodies take centre stage in lymphom...

SABCS: Pharmas show their working in HR+/HER2- breast cancer

SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for cla...

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks